Actively Recruiting
Safe Threshold to Discontinue Phototherapy in Hemolytic Disease of Newborn
Led by Ministry of Health, Saudi Arabia · Updated on 2025-01-03
84
Participants Needed
1
Research Sites
378 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
We hypothesized that adopting a lower rather than a higher threshold for phototherapy discontinuation will be associated with reduced rates of rebound hyperbilirubinemia in term and late preterm neonates with hemolytic disease of newborn. Objectives: The investigators aimed to compare the safety of implementing low-threshold, compared to high- threshold, of TSB for phototherapy interruption in term and late preterm neonates with hemolytic disease of newborn.
CONDITIONS
Official Title
Safe Threshold to Discontinue Phototherapy in Hemolytic Disease of Newborn
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Healthy term and late-preterm neonates born at 35 weeks gestation or later with hemolytic disease of newborn
- Evidence of hemolysis defined by positive direct antiglobulin test and blood group incompatibility (ABO or Rh) or hemoglobin drop by 2 g/dl within 24 hours
You will not qualify if you...
- Major congenital abnormalities
- Surgical problems
- Direct hyperbilirubinemia
- Sepsis
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Madinah maternity and children's hospital
Madinah, Saudi Arabia, 42319
Actively Recruiting
Research Team
F
Fatimah S Alhazmi, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here